Article Text


Association between chronic obstructive pulmonary disease and increased risk of benign prostatic hyperplasia: a retrospective nationwide cohort study
  1. Yi-Hao Peng1,2,3,
  2. Chien-Wen Huang4,5,6,
  3. Wei-Chih Liao7,8,
  4. Hsuan-Ju Chen8,9,
  5. Ming-Chien Yin1,10,
  6. Yu-Ming Huang2,
  7. Trong-Neng Wu11,
  8. Wen-Chao Ho1
  1. 1 Department of Public Health, China Medical University, Taichung, Taiwan
  2. 2 Division of Respiratory Therapy, Asia University Hospital, Asia University, Taichung, Taiwan
  3. 3 Department of Respiratory Therapy, China Medical University, Taichung, Taiwan
  4. 4 Division of Chest Medicine, Department of Internal Medicine, Asia University Hospital, Taichung, Taiwan
  5. 5 Department of Biotechnology, College of Medical and Health Science, Asia University, Taichung, Taiwan
  6. 6 Institute of Molecular Biology, College of Life Sciences, National Chung Hsing University, Taichung, Taiwan
  7. 7 Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, China Medical University Hospital, China Medical University, Taichung, Taiwan
  8. 8 College of Medicine, China Medical University, Taichung, Taiwan
  9. 9 Management Office for Health Data, China Medical University Hospital, Taichung, Taiwan
  10. 10 Department of Respiratory Therapy, China Medical University Hospital, China Medical University, Taichung, Taiwan
  11. 11 Department of Health Care Administration, Asia University, Taichung, Taiwan
  1. Correspondence to Dr Wen-Chao Ho; whocmu{at}


Objective Chronic obstructive pulmonary disease (COPD) and benign prostatic hyperplasia (BPH) are common disorders in ageing male populations. Nevertheless, the relationship between the two diseases has rarely been explored. The objective of this study was to examine whether patients with COPD are at an increased risk of BPH.

Design Retrospective nationwide cohort study.

Setting Data retrieved from the Taiwan National Health Insurance Research Database.

Participants Overall, 19 959 male patients aged 40 years and over with newly diagnosed COPD between 2000 and 2006 were included as the COPD group, and 19 959 sex-matched and age-matched enrollees without COPD were included as the non-COPD group. Both groups were followed-up until the end of 2011.

Outcome measures A Cox proportional hazards regression model was used to compute the risk of BPH in patients with COPD compared with enrollees without COPD.

Results The overall incidence rate of BPH was 1.53 times higher in the COPD group than that in the non-COPD group (44.7 vs 25.7 per 1000 person-years, 95% CI 1.46 to 1.60) after adjusting for covariates. An additional stratified analysis revealed that this increased risk of BPH in patients with COPD remained significantly higher than that in enrollees without COPD in all men aged 40 years and over.

Conclusion After adjustment for covariates, male patients with COPD were found to be at a higher risk of BPH. We suggest that clinicians should be cautious about the increased risk of BPH in male patients with COPD.

  • benign prostatic hyperplasia
  • chronic obstructive pulmonary disease
  • cohort study
  • comorbidity
  • lower urinary tract symptoms.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See:

Statistics from


  • Contributors Y-HP, C-WH, W-CL and W-CH were involved in conception and design, T-NW and H-JC were involved in administrative support, Y-HP, M-CY, Y-MH and W-CH were involved in collection and assembly of data. All authors involved in manuscript writing and final approval of the manuscript.

  • Funding This study is supported in part by Taiwan Ministry of Health and Welfare Clinical Trial and Research Center of Excellence (MOHW106-TDU-B-212-113004), China Medical University Hospital, Academia Sinica Taiwan Biobank Stroke Biosignature Project (BM10501010037), NRPB Stroke Clinical Trial Consortium (MOST 105-2325-B-039-003), Tseng-Lien Lin Foundation, Taichung, Taiwan, Taiwan Brain Disease Foundation, Taipei, Taiwan, and Katsuzo and Kiyo AoshimaMemorial Funds, Japan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. No additional external funding was received for this study.

  • Competing interests None declared.

  • Patient consent Detail has been removed from this case description/these case descriptions to ensure anonymity. The editors and reviewers have seen the detailed information available and are satisfied that the information backs up the case the authors are making.

  • Provenance and peer review Not commissioned; externally peer reviewed.

  • Data sharing statement No additional data are available.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.